Intrinsic Edge Capital Management’s Castle Biosciences CSTL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-232,711
Closed -$6.2M 81
2024
Q4
$6.2M Buy
232,711
+20,000
+9% +$609K 0.75% 53
2024
Q3
$6.07M Sell
212,711
-41,700
-16% -$1.06M 0.73% 44
2024
Q2
$5.54M Buy
254,411
+30,844
+14% +$687K 0.5% 66
2024
Q1
$4.95M Sell
223,567
-102,703
-31% -$2.23M 0.39% 80
2023
Q4
$7.04M Buy
326,270
+170,000
+109% +$2.99M 0.7% 50
2023
Q3
$2.64M Sell
156,270
-199,936
-56% -$3.5M 0.3% 87
2023
Q2
$4.89M Sell
356,206
-39,630
-10% -$803K 0.35% 93
2023
Q1
$8.99M Buy
395,836
+30,869
+8% +$754K 0.9% 50
2022
Q4
$8.59M Buy
364,967
+52,567
+17% +$1.22M 0.86% 46
2022
Q3
$8.15M Buy
312,400
+30,000
+11% +$841K 0.89% 43
2022
Q2
$6.2M Buy
282,400
+70,000
+33% +$1.63M 0.48% 74
2022
Q1
$9.53M Buy
+212,400
New +$8.78M 0.73% 51
2021
Q4
Sell
-147,895
Closed -$9.84M 208
2021
Q3
$9.84M Sell
147,895
-22,070
-13% -$1.55M 0.68% 54
2021
Q2
$12.5M Buy
169,965
+129,965
+325% +$8.58M 0.73% 39
2021
Q1
$2.74M Buy
+40,000
New +$3.01M 0.19% 173

Other funds holding CSTL

Intrinsic Edge Capital Management's CSTL Position: Q1 2025 in Review

Intrinsic Edge Capital Management sold out of Castle Biosciences (CSTL) in Q1 2025, closing a stake of 232,711 shares — an estimated $6.2M sold.

Intrinsic Edge Capital Management first reported a position in CSTL in Q1 2021 and held it in 15 quarters. The position peaked at $12.5M in Q2 2021. 180 funds tracked by Wall St. Rank hold CSTL as of Q1 2025.

  • Intrinsic Edge Capital Management reported no remaining Castle Biosciences position as of Q1 2025 after selling out during the quarter.
  • Intrinsic Edge Capital Management sold 232,711 Castle Biosciences shares in Q1 2025, an estimated $6.2M.
  • Intrinsic Edge Capital Management first reported a position in Castle Biosciences in Q1 2021 and held it in 15 quarters.
  • Intrinsic Edge Capital Management's Castle Biosciences position peaked at $12.5M in Q2 2021.
  • 180 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2025.

Based on Intrinsic Edge Capital Management's 13F filing for Q1 2025, filed 12 May 2025.